Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.
Abbott and Bigfoot have worked together on connected diabetes solutions since 2017. Bigfoot have developed Bigfoot Unity, a smart insulin management system that features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data along with insulin dosing recommendations displayed on the pen cap’s digital screen.
The Bigfoot Unity system exclusively works with Abbott’s FreeStyle Libre technology, including FreeStyle Libre 2 sensors and all major brands of both long-acting (basal) and rapid-acting (bolus) disposable insulin pens offered in the United States.
“The acquisition of Bigfoot Biomedical will combine two leaders in different aspects of diabetes care: continuous glucose monitoring and insulin dosing support,” said Jared Watkin, senior vice president of Abbott’s Diabetes Care business. “Bringing our companies together will allow us to further develop connected solutions for making diabetes management even more personal and precise.”
“Bigfoot Biomedical is the first company to design, develop and deliver a novel insulin delivery solution built around continuous glucose monitoring,” said Jeffrey Brewer, chief executive officer, Bigfoot Biomedical. “We selected Abbott as our CGM partner because both companies share a vision to provide simple, affordable and easy-to-use tools for people with diabetes. We look forward to continuing to innovate together and to the scale Abbott can provide, bringing Bigfoot Unity to as many people who may benefit.”
To read more, CLICK HERE.
